AngioDynamics (NASDAQ:ANGO) Stock Rating Reaffirmed as “Buy” by Canaccord Genuity Group

AngioDynamics (NASDAQ:ANGO)‘s stock had its “buy” rating reaffirmed by Canaccord Genuity Group in a research note issued on Friday, Benzinga reports. They currently have a $20.00 price objective on the medical instruments supplier’s stock. Canaccord Genuity Group’s price target would suggest a potential upside of 73.61% from the company’s previous close.

Other analysts also recently issued reports about the company. Weiss Ratings restated a “sell (d-)” rating on shares of AngioDynamics in a research note on Friday, July 17th. Zacks Research upgraded AngioDynamics from a “strong sell” rating to a “hold” rating in a research note on Monday. Wall Street Zen upgraded AngioDynamics from a “hold” rating to a “buy” rating in a research note on Saturday, August 22nd. Finally, HC Wainwright raised their target price on AngioDynamics from $16.00 to $19.00 and gave the company a “buy” rating in a research note on Wednesday, July 15th. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $19.50.

AngioDynamics Stock Performance

AngioDynamics stock traded up $0.29 during trading on Friday, reaching $11.52. 2,150,808 shares of the company’s stock were exchanged, compared to its average volume of 506,590. The company’s 50-day moving average is $15.39 and its two-hundred day moving average is $13.11. AngioDynamics has a 52-week low of $9.39 and a 52-week high of $16.29. The firm has a market cap of $484.42 million, a price-to-earnings ratio of -13.24 and a beta of 0.30.

AngioDynamics (NASDAQ:ANGO) last released its quarterly earnings results on Thursday, October 8th. The medical instruments supplier reported ($0.04) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.11) by $0.07. The firm had revenue of $80.92 million for the quarter, compared to the consensus estimate of $80.51 million. AngioDynamics had a negative net margin of 11.48% and a negative return on equity of 5.73%. AngioDynamics has set its FY 2027 guidance at -0.290–0.240 EPS. Analysts anticipate that AngioDynamics will post -0.25 EPS for the current year.

Insider Buying and Selling

In related news, SVP Warren Jr sold 23,370 shares of AngioDynamics stock in a transaction dated Thursday, July 30th. The stock was sold at an average price of $14.72, for a total value of $344,006.40. Following the completion of the transaction, the senior vice president directly owned 64,745 shares in the company, valued at approximately $953,046.40. This trade represents a 26.52% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 6.00% of the company’s stock.

Hedge Funds Weigh In On AngioDynamics

Large investors have recently bought and sold shares of the business. BlackRock Inc. bought a new position in AngioDynamics in the second quarter worth about $49,480,000. Armistice Capital LLC lifted its holdings in AngioDynamics by 3.9% in the fourth quarter. Armistice Capital LLC now owns 1,700,000 shares of the medical instruments supplier’s stock worth $21,828,000 after acquiring an additional 64,000 shares during the last quarter. Weber Capital Management LLC ADV bought a new position in AngioDynamics in the second quarter worth about $17,649,392. Bastion Asset Management Inc. lifted its holdings in AngioDynamics by 17.4% in the first quarter. Bastion Asset Management Inc. now owns 1,313,002 shares of the medical instruments supplier’s stock worth $14,107,000 after acquiring an additional 194,822 shares during the last quarter. Finally, Dimensional Fund Advisors LP lifted its holdings in AngioDynamics by 3.5% in the first quarter. Dimensional Fund Advisors LP now owns 948,815 shares of the medical instruments supplier’s stock worth $10,786,000 after acquiring an additional 32,476 shares during the last quarter. Institutional investors own 89.43% of the company’s stock.

Key AngioDynamics News

Here are the key news stories impacting AngioDynamics this week:

• Positive Sentiment: AngioDynamics reported adjusted EPS of a $0.04 loss, beating the consensus estimate of a $0.11 loss, while revenue reached approximately $80.9 million versus expectations of $80.5 million. Revenue increased 6.9% year over year, and gross margin expanded by 410 basis points to 59.4%. ANGO Q1 Earnings Beat Estimates on Med Tech Growth, Revenues Up Y/Y
• Positive Sentiment: Growth was strongest in the Med Tech segment, where sales rose 13.2%. Auryon revenue increased 14.7% to $18.9 million and NanoKnife revenue climbed 29% to $8.3 million, supporting the company’s growth strategy. Fiscal Year 2027 First Quarter Financial Results
• Positive Sentiment: Canaccord Genuity reaffirmed its “buy” rating and maintained a $20 price target, implying substantial potential upside from recent trading levels. AngioDynamics Stock Is Falling Thursday: What’s Going On?
• Neutral Sentiment: Management reiterated fiscal 2027 revenue guidance of $336 million to $341 million and adjusted EPS guidance of a $0.29 to $0.24 loss, broadly in line with analyst expectations. The company also received FDA IDE approval for a NanoKnife feasibility study in benign prostatic hyperplasia, a potential longer-term catalyst. AngioDynamics Reiterates FY27 Outlook; Appoints Eric Honroth President and CEO
• Negative Sentiment: Eric Honroth will become president and CEO on November 2, succeeding Jim Clemmer. The leadership change may be weighing on sentiment because it introduces execution uncertainty even as the company transitions to a new chief executive. Appointment of Eric Honroth as President and Chief Executive Officer
• Negative Sentiment: AngioDynamics remains unprofitable, reporting a GAAP net loss of approximately $7.1 million, or $0.17 per share, and used $15.3 million in operating cash during the quarter. The stock’s decline on unusually heavy volume suggests investors focused more on profitability, cash burn and the CEO transition than on the earnings beat.

AngioDynamics Company Profile

AngioDynamics, Inc is a medical device company that develops, manufactures and markets minimally invasive products for use in vascular disease, vascular access and oncology. Its technologies are designed to help physicians treat blood clots, restore blood flow, manage vascular access and ablate targeted tissue.

The company’s portfolio includes the Auryon platform for atherectomy, which uses laser technology to treat peripheral arterial disease; the AngioVac and AlphaVac systems for removing thrombus and other unwanted material from blood vessels; and BioSentry products used to seal biopsy tracts.